Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 19/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847376 | 0.82 | PDE3A (0.55) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL16150009 | 0.82 | PDE3A (0.55) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL7380645 | 0.81 | PDE3A (0.54) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL5183107 | 0.80 | PDE3A (0.44) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL2844753 | 0.79 | PDE3A (0.52) | PDE3APDE3BPDE4B | |
| SCHEMBL16150897 | 0.78 | PDE3B (0.51) | PDE3APDE3B | |
| SCHEMBL16150746 | 0.76 | PDE3A (0.52) | PDE3APDE3BPDE4B | |
| SCHEMBL6683658 | 0.76 | PDE3A (0.40) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL5184219 | 0.75 | HRH3 (0.46) | PDE3APDE3BPDE4BPDE4APDE4C | |
| SCHEMBL17295075 | 0.74 | PDE3A (0.48) | PDE3APDE3BPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2970145-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BROAD INST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20180244629-A1 | Compounds And Compositions For The Treatment Of Cancer | THE BROAD INSTITUTE, INC. | 2018-08-30 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890127-B2 | Compounds and compositions for the treatment of cancer | THE BROAD INSTITUTE, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| EP-2970145-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | The Broad Institute, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014164704-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | THE BROAD INSTITUTE, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016913-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TP53, RB1, CDK4 | PDE3A 2661/4885PDE3B 2667/4885PDE4B 2928/4885 |
| US-20180244629-A1 | Compounds And Compositions For The Treatment Of Cancer | TP53, RB1, CDK4 | PDE3A 2661/4885PDE3B 2667/4885PDE4B 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.